COMPANY PROFILE

Medical International Research S.p.A. (MIR), an Italian company founded in 1993, is a global leader in the field of innovative design, production and sales of pulmonary diagnostic devices, as well as applications for the analysis of lung function and arrhythmias. MIR solutions are CE-marked and FDA-approved.
With ties in over 100 countries, MIR is considered a global visionary partner and is the preferred choice of App Developers for its innovative technological solutions, as well as SDKs/APIs applications.In 2009, MIR founded MIR USA Inc.
During pandemic, the MIR global sales network equipped over 10,000 patients throughout the National Health Service (NHS) in UK and over 30,000 patients, including those affected by Cystic Fibrosis, in USA.
In March 2021 MIR was acquired by one of the strongest Italian private equity firms, Aksìa Group, that focuses on companies with established leadership in specific arenas with high growth potential.
In August 2021, MIR acquired the Groupe LAMIRAU in France, leader in Respiratory Diagnostic and Respiratory Telemedicine market. Just a further step in MIR expansion strategy.
Today, MIR collaborates with institutional partners from pharmaceutical industries, universities, and top medical facilities around the world in a global initiative to assist in the fight against chronic pulmonary illnesses and help get patients the tools they need.